MedPath

Primary Care Management of Lower Urinary Tract Symptoms in Men

Not Applicable
Completed
Conditions
Lower Urinary Tract Symptoms
Interventions
Diagnostic Test: Urodynamics
Registration Number
NCT03520673
Lead Sponsor
Cardiff University
Brief Summary

The PriMUS Study aims to develop a clinical decision support tool to help GPs more accurately diagnose and manage LUTS in men. The study will recruit 880 men across three research hubs in Bristol, Newcastle and Wales. Men will all receive a series of simple index tests in primary care (following NICE Clinical Guidelines) and a urodynamics reference test. The study will then compare which combination of the simple index tests give the best prediction of the urodynamics result, which can then be incorporated into the clinical decision support tool.

Detailed Description

Men are more likely to experience bothersome Lower Urinary Tract Symptoms (LUTS) as they get older. GPs follow standard processes to investigate signs of cancer, or more serious conditions but do not have access to tools to identify and manage more common symptoms of LUTS. This means men are likely to be referred to a urologist in secondary care, where they will receive advice or treatment that could have been given in primary care if GPs had more access to better diagnostic tools. The PriMUS Study will compare the results of the simple index tests, with the results of the urodynamic reference test, to identify which combination of simple index tests give the best prediction of the urodynamics diagnosis. The top performing simple index tests will be incorporated into the clinical decision support tool so that GPs can manage patients without needing invasive urodynamics. Follow up will be conducted 6 months post involvement; collating the treatment and management decisions made as a result of these procedures. The study will also consider and explore practicalities and acceptability of the urodynamic procedure and clinical decision support tool for both patients and clinical staff by conducting separate qualitative work.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
725
Inclusion Criteria
  • Men aged 16 years and over.

  • Men who present to their GP with a complaint of one or more bothersome lower urinary tract symptoms (LUTS)#

  • Men able and willing to give informed consent for participation in study

  • Men able and willing to undergo all index tests and reference test, and complete study documentation.

    • This would include men on current treatment, but who are still symptomatic

Exclusion criteria

  • Men with neurological disease or injury affecting lower urinary tract function

  • Men with LUTS considered secondary to current or past invasive treatment or radiotherapy for pelvic disease

  • Men with other contraindications to urodynamics e.g. Heart valve or joint replacement surgery within the last 3 months, immunocompromised/immunosuppressed.

  • Men with indwelling urinary catheters or who carry out intermittent self-catheterisation

  • Men whose initial assessment suggests that clinical findings are suggestive of possible:

    • prostate or bladder cancer*
    • recurrent or persistent symptomatic UTI**
    • retention e.g. palpable bladder after voiding'
  • Men unable to consent in English or Welsh where a suitable translator is not available. This is a multi-centre study based in primary care, and we cannot guarantee translation facilities at all sites

    • According to standard NHS cancer pathways. If later deemed unlikely, then eligible for study participation.

      • If UTI successfully treated but LUTS remain, then eligible for study
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Development of Clinical Decision Support ToolUrodynamicsAll men will receive the same series of simple index tests which will be compared with the results of the urodynamics reference test to identify which index tests give the best prediction of the urodynamic results. The data from the first cohort will develop the clinical decision support tool.
Primary Outcome Measures
NameTimeMethod
Primary Outcome 1- Sensitivity and specificity of the PriMUS clinical decision aid in diagnosing detrusor underactivity, bladder outlet obstruction and detrusor over activity, in men with lower urinary tract symptoms presenting to primary care.36 months

The accuracy of a clinical decision tool, which incorporates simple index tests, by reference and comparison to Urodynamic investigation as the gold standard at 36 months.

Secondary Outcome Measures
NameTimeMethod
Secondary Outcome 1 - Construction of a patient management algorithm to guide initial treatment for men with LUTS36 months

Identify which combination of simple tests (including e.g. ethnicity, smoking status, height (cm) and weight (kg), medical history, medication, outcome of bladder diary, self-reported symptoms scores using IPSS and ICIQ questionnaires, Digital Rectal Examination Result, Prostate Specific Antigen (PSA) result, Abdominal Physical Examination Result) best predict the urodynamic diagnosis at 36 months.

Secondary Outcome 2 - Qualitative analysis of patients' and clinicians' views on the use of a LUTS decision aid in the primary care setting24 months

Analyse the acceptability of a decision aid in primary care with patients and clinicians, to assess the decision tool's value and potential usability.

Secondary Outcome 3 - Estimate potential percentage change in referral rates to secondary care for men with LUTS36 months

To calculate the potential change in referral rates of men with LUTs into secondary care to calculate the potential overall excess treatment cost savings.

Secondary Outcome 4 - Estimation of potential costs / savings of implementation of the primary care LUTS decision aid both from a population and individual patient perspective36 months

Estimation of potential costs / savings of implementation of the primary care LUTS decision aid both from a population and individual patient perspective

Trial Locations

Locations (1)

Cardiff University

🇬🇧

Cardiff, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath